Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1587395
PUBLISHER: Grand View Research | PRODUCT CODE: 1587395
U.S. Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain, By Service, By Product, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Biopharmaceutical Third-party Logistics Market Growth & Trends:
The U.S. biopharmaceutical third-party logistics market size is estimated to reach USD 87.44 billion by 2030, registering to grow at a CAGR of 7.56% from 2025 to 2030 according to a new report by Grand View Research, Inc. Increasing demand for novel biologics and the need to manage those is boosting the market growth. Besides, rising demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the growth.
The COVID-19 pandemic has had a major impact on global logistics to some extent due to diminished air freight capacity and reduced workforce at warehouses and airports. The decisions of local authorities to shut down the logistic infrastructure, enforce movement restrictions, or put in place additional requirements to suppress transmission of the virus have also impacted the logistic services. This has significantly hindered many supply operations.
The future seems lucrative for the biopharmaceutical third-party logistics industry in the U.S. with the retraction of government regulations related to transportation and shelter-in-place mandates. A sudden surge in the demand for cold chain logistics was observed during the pandemic. Growth in the manufacture and distribution of the COVID-19 vaccine is expected throughout 2021. For instance, in March 2021, FedEx Express started shipping COVID-19 vaccines for McKesson Corp. to centers all across the U.S. The company has already shipped millions of COVID-19 vaccines since mid-December 2020.
U.S. Biopharmaceutical Third-party Logistics Market Highlights
- The non-cold chain logistics segment accounted for the largest revenue share of 58.39% in 2024. The segment is primarily driven by the distribution of standard biopharmaceutical products that do not require stringent temperature control, allowing for a broader range of transportation and storage options.
- The warehousing and storage segment dominated the market in 2024. This segment provides specialized storage solutions for both temperature-sensitive and non-sensitive products, integrating high-tech systems such as automated warehouses and real-time inventory management.
- The specialty drugs segment accounted for the largest revenue share in the market in 2024 and is expected to witness the highest CAGR over the estimated timeline. This is attributed to the unique handling requirements of these high-value, often temperature-sensitive medications.
Product Code: GVR-4-68038-381-2
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Estimates and forecast timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.1.1. Approach 1: Commodity flow approach
- 1.7.2. Volume price analysis (Model 2)
- 1.7.2.1. Approach 2: Volume price analysis
- 1.7.1. Commodity flow analysis (Model 1)
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. Industry Ecosystem Analysis
- 3.6. Market Analysis Tools
- 3.6.1. Porter's Five Forces Analysis
- 3.6.2. PESTEL Analysis
- 3.6.3. COVID-19 Impact Analysis
Chapter 4. U.S. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Biopharmaceutical Third-Party Logistics Market: Supply Chain Movement Analysis
- 4.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.4. Cold Chain
- 4.4.1. Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.5. Non-Cold Chain
- 4.5.1. Non-Cold Chain Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 5. U.S. Biopharmaceutical Third-Party Logistics Market: Service Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Biopharmaceutical Third-party Logistics Market: Service Movement Analysis
- 5.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.4. Transportation
- 5.4.1. Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.4.2. Air Freight
- 5.4.2.1. Air Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.4.3. Sea Freight
- 5.4.3.1. Sea Freight Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.4.4. Overland Transportation
- 5.4.4.1. Overland Transportation Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.5. Warehousing & Storage
- 5.5.1. Warehousing & Storage Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.6. Others
- 5.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 6. U.S. Biopharmaceutical Third-Party Logistics Market: Product Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Biopharmaceutical Third-Party Logistics Market: Product Movement Analysis
- 6.3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.4. Specialty Drugs
- 6.4.1. Specialty Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.5. Generics
- 6.5.1. Generics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.6. Plasma Derived Products
- 6.6.1. Plasma Derived Products Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.7. Others
- 6.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
Chapter 7. Competitive Landscape
- 7.1. Company Categorization
- 7.1.1. Market Leaders
- 7.1.2. Emerging Players
- 7.2. Company Market Position Analysis
- 7.3. Company Profiles
- 7.3.1. UPS Healthcare
- 7.3.1.1. Company Overview
- 7.3.1.2. Financial Performance
- 7.3.1.3. Service Benchmarking
- 7.3.1.4. Strategic Initiatives
- 7.3.2. Cardinal Health
- 7.3.2.1. Company Overview
- 7.3.2.2. Financial Performance
- 7.3.2.3. Service Benchmarking
- 7.3.2.4. Strategic Initiatives
- 7.3.3. KUEHNE + NAGEL
- 7.3.3.1. Company Overview
- 7.3.3.2. Financial Performance
- 7.3.3.3. Service Benchmarking
- 7.3.3.4. Strategic Initiatives
- 7.3.4. AmerisourceBergen Corp.
- 7.3.4.1. Company Overview
- 7.3.4.2. Financial Performance
- 7.3.4.3. Service Benchmarking
- 7.3.4.4. Strategic Initiatives
- 7.3.5. McKesson Corporation
- 7.3.5.1. Company Overview
- 7.3.5.2. Financial Performance
- 7.3.5.3. Service Benchmarking
- 7.3.5.4. Strategic Initiatives
- 7.3.6. Thermo Fisher Scientific
- 7.3.6.1. Company Overview
- 7.3.6.2. Financial Performance
- 7.3.6.3. Service Benchmarking
- 7.3.6.4. Strategic Initiatives
- 7.3.7. DHL International GmbH
- 7.3.7.1. Company Overview
- 7.3.7.2. Financial Performance
- 7.3.7.3. Service Benchmarking
- 7.3.7.4. Strategic Initiatives
- 7.3.8. DB Schenker
- 7.3.8.1. Company Overview
- 7.3.8.2. Financial Performance
- 7.3.8.3. Service Benchmarking
- 7.3.8.4. Strategic Initiatives
- 7.3.9. Kerry Logistics Network Ltd.
- 7.3.9.1. Company Overview
- 7.3.9.2. Financial Performance
- 7.3.9.3. Service Benchmarking
- 7.3.9.4. Strategic Initiatives
- 7.3.10. CEVA Logistics
- 7.3.10.1. Company Overview
- 7.3.10.2. Financial Performance
- 7.3.10.3. Service Benchmarking
- 7.3.10.4. Strategic Initiatives
- 7.3.11. Agility Logistics
- 7.3.11.1. Company Overview
- 7.3.11.2. Financial Performance
- 7.3.11.3. Service Benchmarking
- 7.3.11.4. Strategic Initiatives
- 7.3.12. SF Express
- 7.3.12.1. Company Overview
- 7.3.12.2. Financial Performance
- 7.3.12.3. Service Benchmarking
- 7.3.12.4. Strategic Initiatives
- 7.3.13. XPO Logistics
- 7.3.13.1. Company Overview
- 7.3.13.2. Financial Performance
- 7.3.13.3. Service Benchmarking
- 7.3.13.4. Strategic Initiatives
- 7.3.14. Cencora, Inc.
- 7.3.14.1. Company Overview
- 7.3.14.2. Financial Performance
- 7.3.14.3. Service Benchmarking
- 7.3.14.4. Strategic Initiatives
- 7.3.15. EVERSANA
- 7.3.15.1. Company Overview
- 7.3.15.2. Financial Performance
- 7.3.15.3. Service Benchmarking
- 7.3.15.4. Strategic Initiatives
- 7.3.1. UPS Healthcare
Product Code: GVR-4-68038-381-2
List of Tables
- Table 1. List of Secondary Sources
- Table 2. List of Abbreviations
- Table 3. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Supply Chain, 2018 - 2030 (USD Billion)
- Table 4. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Service, 2018 - 2030 (USD Billion)
- Table 5. U.S. Biopharmaceutical Third-Party Logistics (3PL) Market by Product, 2018 - 2030 (USD Billion)
List of Figures
- Fig. 1 Information Procurement
- Fig. 2 Primary Research Pattern
- Fig. 3 Market Research Approaches
- Fig. 4 Value Chain-Based Sizing & Forecasting
- Fig. 5 Market Formulation & Validation
- Fig. 6 Biopharmaceutical Third-Party Logistics, Market Segmentation
- Fig. 7 Market Driver Analysis (Current & Future Impact)
- Fig. 8 Market Restraint Analysis (Current & Future Impact)
- Fig. 9 Porter's Five Forces Analysis
- Fig. 10 PESTEL By SWOT Analysis
- Fig. 11 U.S. Biopharmaceutical Third-Party Logistics, for Cold Chain Logistics, 2018 - 2030 (USD Million)
- Fig. 12 U.S. Biopharmaceutical Third-Party Logistics, for Non-cold Chain Logistics, 2018 - 2030 (USD Million)
- Fig. 13 U.S. Biopharmaceutical Third-Party Logistics, for Transportation, 2018 - 2030 (USD Million)
- Fig. 14 U.S. Biopharmaceutical Third-Party Logistics, for Air Freight, 2018 - 2030 (USD Million)
- Fig. 15 U.S. Biopharmaceutical Third-Party Logistics, for Sea Freight, 2018 - 2030 (USD Million)
- Fig. 16 U.S. Biopharmaceutical Third-Party Logistics, for Overland, 2018 - 2030 (USD Million)
- Fig. 17 U.S. Biopharmaceutical Third-Party Logistics, for Warehousing and Storage, 2018 - 2030 (USD Million)
- Fig. 18 U.S. Biopharmaceutical Third-Party Logistics, for Other Services, 2018 - 2030 (USD Million)
- Fig. 19 U.S. Biopharmaceutical Third-Party Logistics, for Specialty Drugs, 2018 - 2030 (USD Million)
- Fig. 20 U.S. Biopharmaceutical Third-Party Logistics, for Generics, 2018 - 2030 (USD Million)
- Fig. 21 U.S. Biopharmaceutical Third-Party Logistics, for Plasma Derived Products, 2018 - 2030 (USD Million)
- Fig. 22 U.S. Biopharmaceutical Third-Party Logistics, for Others, 2018 - 2030 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.